Ghazi S Alotaibi, Abdullah S Al Saleh, Ayman Alhejazi, Majed Alahmadi, Ibraheem Motabi, Fahad Z Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Tailor, Mohammed Marei, Ahmed S Barefah, Mansour Aljabry, Saud Alhayli, Binyam Usman, Amr Hanbali, Amal Alabdulwahab, Ihab ElHemaidi, Hatem Mahmoud Alahwal, Enas Mutahar, Ahmad Alsaeed
{"title":"Definition, Diagnosis, Risk Stratification and Management of Newly Diagnosed Multiple Myeloma: The Saudi Myeloma Working Group Guidelines.","authors":"Ghazi S Alotaibi, Abdullah S Al Saleh, Ayman Alhejazi, Majed Alahmadi, Ibraheem Motabi, Fahad Z Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Tailor, Mohammed Marei, Ahmed S Barefah, Mansour Aljabry, Saud Alhayli, Binyam Usman, Amr Hanbali, Amal Alabdulwahab, Ihab ElHemaidi, Hatem Mahmoud Alahwal, Enas Mutahar, Ahmad Alsaeed","doi":"10.1016/j.clml.2025.06.005","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple myeloma is a rising concern globally, with increasing incidence and mortality, especially in low- and middle-income countries. In Saudi Arabia, multiple myeloma care faces significant challenges outside tertiary care centers, including delays in diagnosis, limited availability of standardized treatment protocols, and considerable disparities in healthcare infrastructure. These issues are particularly prominent in non-urban and secondary healthcare facilities, where access to specialized diagnostics and therapies may be restricted, impacting early detection and optimal management of the disease. Although treatment advances have improved survival rates, multiple myeloma remains incurable and poses significant financial burdens due to the high cost of therapies, particularly in resource-constrained settings. This updated guideline from the Saudi Myeloma Working Group aims to address the gaps in newly diagnosed multiple myeloma management in Saudi Arabia.xsy.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.06.005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple myeloma is a rising concern globally, with increasing incidence and mortality, especially in low- and middle-income countries. In Saudi Arabia, multiple myeloma care faces significant challenges outside tertiary care centers, including delays in diagnosis, limited availability of standardized treatment protocols, and considerable disparities in healthcare infrastructure. These issues are particularly prominent in non-urban and secondary healthcare facilities, where access to specialized diagnostics and therapies may be restricted, impacting early detection and optimal management of the disease. Although treatment advances have improved survival rates, multiple myeloma remains incurable and poses significant financial burdens due to the high cost of therapies, particularly in resource-constrained settings. This updated guideline from the Saudi Myeloma Working Group aims to address the gaps in newly diagnosed multiple myeloma management in Saudi Arabia.xsy.
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.